ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / OVID / options
DMAC (43) CBIO (29) MPLT (35) AQST (18) ⌘ Pro Terminal →

Ovid Therapeutics Inc. (OVID) Options Positioning, Max Pain & Unusual Sweeps

$2.39 -5.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.36

Ovid Therapeutics Inc. (OVID) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $496.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OVID Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OVID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Ovid Therapeutics Inc. (NASDAQ: OVID) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $2.39 (-5.91% 1D, market cap $496.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OVID ranks #462 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OVID compare to DMAC and CBIO in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OVID carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.5%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $498.8M) and CBIO (Crescent Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $500.7M). Among the 5-stock peer group, OVID leads on earnings multiple (N/A) while OVID leads on capital efficiency (-28.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OVID?
▼

Per OVID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636651), Ovid Therapeutics Inc. generated $7.3M in revenue (+1181.3% YoY), -$17.4M in net income, and -$38.3M in free cash flow against $150.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.36 (-1.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (6)Whales (13)SEC (11)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-7.9% Base Target
$3 Bull$2 Base$2 Bear
📬 FREE OVID RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OVID)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY OVID SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (33% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (28% of score)

Altman Z-Score 11.46 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
32
Grade E$2.19+7.8% Next Q
Q2 (-2Q)
35
Grade E$2.36-4.2% Next Q
Q3 (-1Q)
37
Grade E$2.26+5.8% Next Q
Current
40
Grade D-$2.39-7.4% Hist 90D α
Trajectory: E (32) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a OVID Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While OVID currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.53) and Max Pain ($2.51) forces dealer call-delta covering toward $3.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OVID• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OVID Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (OVID)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for OVID.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OVID)

  • ✓Walkthrough of OVID's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OVID // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.43%▼ DESCENDING CHANNEL
2026-11-03O $2.56H $2.56L $2.39C $2.39VOL 3.15M
RES: $2.69SUP: $2.08SMA50: $2.53SMA200: $2.37
$3.09$2.68$2.28$1.88$1.47RES $2.69SUP $2.08$2.392026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OVID Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OVID Butterfly Map → + Track OVID →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on OVID today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OVID. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OVID today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OVID)

Health Care Rank #462 of 1016 ⚔️ DMAC vs OVID Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OVID vs. DMAC, CBIO, MPLT, AQST)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Ovid Therapeutics Inc. (OVID) ranks #462 by composite RQD confidence (40/100, grade D-) and #445 by equity capitalization ($496.1M). Within this direct 5-issuer industry benchmark cohort, OVID leads on earnings valuation at N/A trailing P/E, while OVID leads on capital efficiency and profitability with -28.5% ROIC and — gross margin. DMAC currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with OVID at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OVID ACTIVE
Ovid Therapeutics Inc.
D- 40/100 — — -28.5% -5.91% $496.1M Benchmark Subject
DMAC
DiaMedica Therapeutics Inc.
D- 43/100 — — -35.0% +0.43% $498.8M /dmac-vs-ovid →
CBIO
Crescent Biopharma Inc.
E 29/100 — — -35.0% -4.23% $500.7M /cbio-vs-ovid →
MPLT
MapLight Therapeutics Inc.
D- 35/100 — — -32.4% -10.55% $491.0M /mplt-vs-ovid →
AQST
Aquestive Therapeutics Inc.
E 18/100 — 58.3% -35.0% -3.08% $488.2M /aqst-vs-ovid →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001636651

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Ovid Therapeutics Inc. (OVID) reported GAAP revenue of $7.3M (+1181.3% vs. FY2024 revenue of $566.0K , and +1750.0% cumulative change since FY2023) , GAAP net income of -$17.4M, operating cash flow of -$38.3M, and free cash flow of -$38.3M (+31.6% YoY). On the balance sheet, OVID closed FY2025 with $150.9M in total assets against $0 in total debt (Altman Z-Score: 11.46, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.3M -$17.4M -$38.3M -$38.3M $150.9M —
FY2024 (FY) 2024-12-31 $566.0K -$26.4M -$56.0M -$56.0M $92.2M —
FY2023 (FY) 2023-12-31 $392.0K -$52.3M -$45.8M -$45.8M — —

3. OVID Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OVID stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Ovid Therapeutics Inc. (NASDAQ: OVID) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $2.39 (-5.91% 1D, market cap $496.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OVID ranks #462 in composite RQD confidence.

How does OVID compare to DMAC and CBIO in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OVID carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -28.5%. By comparison, DMAC (DiaMedica Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $498.8M) and CBIO (Crescent Biopharma Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $500.7M). Among the 5-stock peer group, OVID leads on earnings multiple (N/A) while OVID leads on capital efficiency (-28.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OVID?

Per OVID's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001636651), Ovid Therapeutics Inc. generated $7.3M in revenue (+1181.3% YoY), -$17.4M in net income, and -$38.3M in free cash flow against $150.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OVID trading relative to its 50-day, 200-day, and 52-week technical levels?

OVID last traded at $2.39 (-5.91% on volume of 2,337,032 shares), positioning the stock -5.53% below its 50-day simple moving average ($2.53) and +0.84% above its 200-day simple moving average ($2.37). Across its 52-week range of $1.18 to $3.11, OVID sits at the 62.7% percentile with a 14-day RSI of 55.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.09 to $2.69).

Direct Sub-Reports: OVID RQD Cockpit OVID 12M Forecast OVID Earnings & Move OVID Dividends & DRIP OVID Insiders & 13F OVID Whale Options OVID Profit Sankey OVID News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

OVID — Ovid Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ovid Therapeutics Inc. (OVID) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $2.39 (-5.91% 1D, market capitalization $496.1M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -28.5%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -7.67%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 11.46, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ovid Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.5B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Ovid Therapeutics Inc. (OVID) reported $7.3M in annual revenue (up from $566.0K in FY2024, +1181.3% YoY) and -$17.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($392.0K revenue, -$52.3M net income) through FY2025, OVID scaled operating cash flow to -$38.3M and free cash flow to -$38.3M, backed by $150.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -7.67% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $1.18 – $3.11 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not establish upstream suppliers, downstream customers, or sector correlations beyond the Health Care sector and Biotechnology: Pharmaceutical Preparations classification. A prospective investor should note that pipeline-related second-order effects, such as partner dependencies or manufacturing relationships, are not resolved by the available data.

  • Key Question #1: Can OVID sustain or expand its -60.0% operating margin and -28.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.3M and free cash flow of -$38.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is OVID's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

OVID Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ovid Therapeutics Inc. (OVID) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OVID Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OVID Bull vs. Bear Conversation Board — What's Your Call at $2.39?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OVID 🐻 33% BEARISH CONVICTION
1. Pick Your Side on OVID:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $3.15 (+24.0%)
📌 Pinned Debate

Institutional accumulation and options positioning earned the strongest RQD pillar at 13 of 20, with revenue rising from $0.4M in FY 20

Here is why I am bullish on OVID here at $2.54: Institutional accumulation and options positioning earned the strongest RQD pillar at 13 of 20, with revenue rising from $0.4M in FY 2023 to $7.3M in FY 2025.. Compare OVID's -60.0% operating margin and -28.5% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $2.41 are getting bought.

EarningsSniper 🐂 BULL

Both sides have a point here — OVID's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.98 (-22.0%)
Spot @ $2.54

Negative ROIC of -28.5%, FCF of -$38.3M in FY 2025, and cash falling to $13.2M point to a cash-consuming business with weak insider con

Careful chasing OVID at $2.54. Negative ROIC of -28.5%, FCF of -$38.3M in FY 2025, and cash falling to $13.2M point to a cash-consuming business with weak insider conviction at 3 of 20.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.98 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%